

SECRETARY OF
05 FEB 16 PM

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name Novartis			
2. Address <input type="checkbox"/> Check if different than previously reported 701 Pennsylvania Ave. NW Suite 725 Washington DC 20004 USA			
3. Principal place of business (if different than line 2) City State/Zip or Country			
4a. Contact Name	b. Telephone number	c. E-mail	5. Senate ID #
Mrs. Andrea McCabe	202-638-7429	andrea.mccabe@novartis.com	9204-12
7. Client Name	<input checked="" type="checkbox"/> Self		6. House ID #
Novartis			33589000

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>1,927,017</u></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of option:</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Revenue Code</p>

[Edit >](#)

Signature Andrea L McCabe Date 2/13/2006

Printed Name and Title Dan Casserly, Executive Director, Federal Government Relations

Digitally signed by Andrea L. McCabe
DN: CN = Andrea L. McCabe, C = US, O = DST ACES Business Representative, OU = ACES TrustID Business Certificate
Date: 2006.02.13 14:07:03 -0500

0000081316

Registrant Name Novartis

Client Name Novartis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

H.R. 2218 Regulation of non corrective contact lens as medical devices
S.930 food and Drug Administration Safety Act of 2005
H.R. 2090 Food and Drug Administration Improvement Act of 2005
H.R. 3196 Fair Access to clinical Trials Act
S. 470 FACT Act

17. House(s) of Congress and Federal agencies contacted Check if None

Senate
House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
James Elkin	Vice President, Federal Government Relations
Daniel Casserly	Executive Director, Federal Government Relations
Thomas Giles	Executive Director, Federal Government Relations
Deborah Bumbaugh	Director, Federal Government Relations
David Drake	Executive Director, Federal Government Relations
Sarah Haller	Executive Director, International and Public Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation too Novartis AG, as its parent, will benefit.

Signature Document digitally signed on Page 1.

Date 2/13/2006

Printed Name and Title Dan Casserly, Executive Director, Federal Government Relations

0000081317

Registrant Name Novartis Client Name Novartis

ADDENDUM for General Lobbying Issue Area HCR

16. Specific lobbying issues (continued from previous page)

H.R. 3428 OTC Medicine Tax Fairness Act of 2005
 S.1514 OTC Medicine Tax Fairness Act of 2005

S.172 To amend the Federal Food, Drug and Cosmetic Act to provide for the regulation of all contact lenses a medical devices, and for other purposes.
 H.R. 371 To amend the Federal Food, Drug and Cosmetic Act to provide for the regulation of all contact lense medical devices, and for other purposes.

S.103 Combat Meth Act of 2005
 H.R. 314 Combat Meth Act of 2005

S.950 Elimination of Neglected Diseases Act of 2005

H.R. 3057 Dept. of State, Foreign Operations, and Related Programs Appropriations Act, 2006

H.R. 2744 Agriculture, Rural Development, Food and Drug Admin. and Related Agenices Appropriations Act, 2006
 Federal Food, Drug and Cosmetic Act (Section 767)

S. Res. 302 Reconciliation Bill

H.R. 2051 Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act of 2005
 S. 173 Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act of 2005

Drug Importation
 Medicare Part B and Part D
 Sickle Cell Anemia
 Immunosuppressant Legislation
 Cancer Therapies Legislation
 Gene Therapy
 Direct to Consumer Advertising
 Medicare Prescription Drugs and Modernization Act

Add page to continue specific issues description for this is.

3000081318

